<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324610</url>
  </required_header>
  <id_info>
    <org_study_id>CAP 5/7</org_study_id>
    <secondary_id>ARTIC / CAP 5/7</secondary_id>
    <nct_id>NCT00324610</nct_id>
  </id_info>
  <brief_title>Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen</brief_title>
  <official_title>Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</source>
  <brief_summary>
    <textblock>
      Standard administration of capecitabine use a 14 days administration. Routine practice in&#xD;
      several intitution leads to use a 5 out of 7 days regimen, with less toxicity.&#xD;
&#xD;
      Purpose : to compare the pharmacokinetics of capecitabine, administered 5 days out of 7, as&#xD;
      compared to the standard administration (14 days out of 21). The second end point is to&#xD;
      compare toxicity with either regimen.&#xD;
&#xD;
      Method : Randomized study with two groups : one with standard administration , the second&#xD;
      with 5/7 days regimen&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>46</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Chemotherapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven breast adenocarcinoma&#xD;
&#xD;
          -  Evaluable or measurable metastases&#xD;
&#xD;
          -  HER-2 status 0 or 1 in immnohistochimy or negative in FISH/CISH&#xD;
&#xD;
          -  Previously treated with anthracyclines and taxanes&#xD;
&#xD;
          -  Age &gt; = 18 y&#xD;
&#xD;
          -  No more than two previous chemotherapy regimens for metastases&#xD;
&#xD;
          -  No nervous central system involvement&#xD;
&#xD;
          -  Hormonal therapy must have been stopped two weeks before enrollment&#xD;
&#xD;
          -  Adequate biologic function&#xD;
&#xD;
          -  Performance status OMS &lt; = 2&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancies, except basocellular cancer, in situ cervix carcinoma&#xD;
&#xD;
          -  Gastro intestinal disease that might affect absorption of capecitabine&#xD;
&#xD;
          -  Cardiac failure or angina pectoris uncontrolled&#xD;
&#xD;
          -  Hypersensitivity for capecitabine, fluorouracil, or one of their excipient&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  Concomitant anticancer therapy (included hormonotherapy)&#xD;
&#xD;
          -  Concomitant radiotherapy&#xD;
&#xD;
          -  Treatment with sorivudine and analogs&#xD;
&#xD;
          -  Pregnant or breast feeding patients. Contraception methods excluding hormonal&#xD;
             treatment is required.&#xD;
&#xD;
          -  Inclusion in an experimental protocol within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>eric levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEGP , PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>joseph Gligorov, MD</last_name>
    <role>Study Chair</role>
    <affiliation>HOPITAL TENON, PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michèle TUBIANA HULIN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CENTRE RENE HUGUENIN, SAINT CLOUD, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VERONIQUE DIERAS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>INSTITUT CURIE, PARIS france</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rémi LARGILLIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>centre antoine lacassagne, NICE, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>eric levy, md</last_name>
    <phone>33-1-56092985</phone>
    <email>eric.levy@egp.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>kahina rideller, CRA</last_name>
    <phone>33-1-56093433</phone>
    <email>kahina.rideller@egp.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ho¨Pital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERIC LEVY, MD</last_name>
      <phone>33-1-56092985</phone>
      <email>eric.levy@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>jacques medioni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <last_update_submitted>May 16, 2006</last_update_submitted>
  <last_update_submitted_qc>May 16, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2006</last_update_posted>
  <keyword>fluoropyrimidines</keyword>
  <keyword>metastases</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>phase 1-2 study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

